Excitement alone isn't evidence, and hope can be expensive.
For the 50 million people living with cerebral palsy worldwide, movement has always been a negotiation between the body's limits and the will to participate fully in life. Now, robotic exoskeletons — wearable machines that guide and support human motion from the outside — have cleared a meaningful threshold: a systematic review confirms they outperform conventional physiotherapy in walking speed, endurance, balance, and high-level mobility. Yet science, as it often does, offers a partial answer where a complete one is needed, and the distance between promising evidence and sound policy remains a road still being built.
- A systematic review of 21 studies and 241 participants — mostly children — confirms robotic exoskeletons deliver measurable gains over conventional therapy in four critical mobility outcomes for people with cerebral palsy.
- The evidence frays at the edges: almost no data exists on whether benefits last once therapy stops, and only seven adult participants appeared across all studies, leaving an entire population largely unexamined.
- No study has yet compared overground exoskeletons directly against bodyweight-supported treadmill training, a cheaper and more accessible alternative — a gap that leaves families and clinicians without the comparison they most need.
- Australia's National Disability Insurance Scheme is actively reviewing funding for robot-assisted gait training, meaning the stakes of incomplete evidence are not abstract — they will shape access for millions of people.
- Researchers urge clinicians to set realistic goals before starting exoskeleton therapy and caution that enthusiasm, however understandable, is not a substitute for the long-term data the field still urgently needs.
Cerebral palsy, the most common childhood-onset disability, disrupts movement in ways that shape every dimension of a person's life — stiffness, weakness, abnormal gait, and often accompanying conditions like epilepsy. Physiotherapy has long been the standard response, but robotic exoskeletons, wearable devices that support and reshape movement from outside the body, have been quietly maturing from laboratory curiosities into clinical tools. In Australia, several models have recently received regulatory approval, ranging from treadmill-paired systems to the newest overground devices that allow users to move freely through their environment.
A systematic review published in Disability and Rehabilitation Journal examined 21 studies involving 241 participants — most of them children around age nine — to assess whether these devices genuinely help people with cerebral palsy. The answer, in four specific areas, is yes: exoskeleton therapy outperformed conventional physiotherapy for walking speed, endurance, balance, and high-level mobility. For someone with cerebral palsy, those gains are not abstractions — they can mean the difference between moving with purpose and moving with exhaustion.
Beyond those four outcomes, the picture becomes uncertain. Evidence for other measures was too thin or too contradictory to interpret. More troubling, almost no study tracked whether improvements persisted after therapy ended. The review also found only seven adult participants across all 21 studies, meaning the findings speak confidently to children but say almost nothing about adults. And no study has yet compared overground exoskeletons directly to bodyweight-supported treadmill training — a more affordable alternative that families and clinicians urgently need to weigh.
In Australia, exoskeleton sessions are available and can be funded through the National Disability Insurance Scheme under clinical supervision, though no scheme will cover outright ownership. An NDIS advisory committee is now reviewing how to fund robot-assisted gait training — a decision that will determine whether exoskeletons become standard care or remain a promising experiment. The researchers behind the review are clear: the four supported outcomes justify cautious clinical use, but realistic goal-setting and careful expectation management are essential. Enthusiasm, they remind us, is not evidence — and in this field, the evidence still has considerable ground to cover.
Cerebral palsy affects roughly 50 million people worldwide, making it the most common childhood-onset disability. The condition disrupts movement in ways that ripple through a person's entire life—muscle stiffness, weakness, abnormal movements, and often other neurological complications like epilepsy or vision problems. For decades, physiotherapy has been the standard response: treadmill work, strength training, task-specific practice. But a different kind of tool has begun to emerge from research labs into clinics: robotic exoskeletons, wearable devices that support the body from outside and help reshape how someone moves through space.
These machines have a longer history than most people realize. The first exoskeletons designed to help people walk appeared in the 1960s, but they were unwieldy and complex—laboratory curiosities that took sixty years to become practical. Over the past two decades, they've been refined considerably. In Australia alone, several models have recently won approval from the Therapeutic Goods Administration. The devices fall into three categories: treadmill-paired systems like the Lokomat, static machines similar to elliptical trainers, and the newest generation—overground exoskeletons such as the Atlas 2030—that let users move freely through their environment and interact with the world around them rather than being tethered to a machine.
A new systematic review, published in Disability and Rehabilitation Journal, examined whether these devices could help people with cerebral palsy specifically. Researchers analyzed 21 studies involving 241 participants, most of them children with an average age of nine. They looked for measurable changes across multiple domains: walking speed, endurance, balance, the ability to run and jump, strength, and whether people achieved their own stated goals. The findings were encouraging in specific ways. Robotic exoskeleton therapy outperformed conventional physiotherapy in four areas: it improved walking speed, increased walking endurance, enhanced balance, and boosted high-level mobility. For someone with cerebral palsy, these gains could translate into real independence—the difference between moving slowly and moving with purpose, between tiring quickly and having stamina for a full day.
But the picture grows murkier beyond those four outcomes. For many other measures, the evidence was either too thin to draw conclusions or the results contradicted each other. Skin irritation appeared in some studies, though it never stopped anyone from continuing treatment. When researchers bothered to ask users how they felt about the experience, responses were generally positive—but most studies didn't ask at all. The deeper problem is what wasn't measured. Almost none of the included studies checked whether benefits persisted after someone stopped using the exoskeleton. Did the improvements stick, or did they fade once the device came off? No one really knows. The review also couldn't break down results by the type or severity of cerebral palsy, or by age group. Most critically, only seven adult participants appeared across all 21 studies, which means the findings apply fairly confidently to children but tell us almost nothing about whether exoskeletons help adults.
There's another gap that matters for real-world decisions. No study directly compared overground exoskeletons to bodyweight-supported treadmill training—a more conventional, more accessible intervention that might produce similar results at a fraction of the cost. That comparison would be crucial for families and clinicians trying to decide where to invest time and money.
Right now in Australia, exoskeleton therapy sessions are becoming available, and the National Disability Insurance Scheme can fund them if a trained clinician supervises. But no funding scheme will pay for someone to own an exoskeleton outright. That matters because families often want to try everything, especially new and exciting options. Exoskeletons are undeniably exciting. They attract attention and hope. But excitement alone isn't evidence, and hope can be expensive. The researchers behind this review are careful not to oversell. They support the use of overground exoskeletons for the four outcomes where the data holds up—walking speed, endurance, balance, high-level mobility. But they're equally clear that clinicians need to set realistic expectations, establish clear goals before starting, and proceed with caution. An advisory committee for Australia's National Disability Insurance Scheme is currently reviewing whether and how to fund robot-assisted gait training. That decision will shape access for millions. It will also determine whether exoskeletons remain a promising experiment or become standard care—and that distinction hinges entirely on whether the evidence can catch up to the enthusiasm.
Notable Quotes
It's crucial for clinicians to provide appropriate and evidence-based advice on the best treatment options. If someone with cerebral palsy wants to try robotic exoskeleton therapy, the clinician should set clear goals for what results to expect, and step forward with caution.— Researchers behind the systematic review
The Hearth Conversation Another angle on the story
Why does it matter that most of the studies looked at children rather than adults?
Because cerebral palsy doesn't stop at age eighteen. An adult's body, their goals, their life context—all of that is different. A child might gain the ability to run at recess. An adult might need to walk to work, or manage fatigue over eight hours. We don't know if exoskeletons help with those things.
The review found that exoskeletons beat conventional therapy in four specific areas. Why not just say they work?
Because "works" is too simple. They work for walking speed. They work for endurance. But what about pain? What about whether someone actually wants to use them long-term? What about cost? The evidence is real but narrow. Saying they work full stop would be misleading.
You mentioned skin irritation. Why didn't that stop people from using the devices?
That's actually interesting. It suggests the benefits felt significant enough to tolerate minor discomfort. But we don't have enough detail to know how much irritation, how often, or whether it would matter to someone with different pain tolerance or skin sensitivity.
What's the real question underneath all this?
Whether exoskeletons are genuinely better than what we already have, or just newer and more exciting. That's why the missing comparison to treadmill training matters so much. If both produce the same results, the choice becomes about access, cost, and what people prefer. Right now we can't answer that.
If you were a parent of a child with cerebral palsy, what would you want to know before trying this?
I'd want to know: What exactly will improve? How long will it last after we stop? Will my child actually use it, or will it sit in a corner? And is there evidence it's better than the therapy we could get today? Honest answers to those questions matter more than the promise.